Oral solid dosage (OSD) forms are widely viewed as presenting the most straightforward path from drug substance to drug product. Capsules are especially simple in concept, requiring developers to select a dose and a capsule type, fill the capsule, package the product and proceed to the clinic. In practice, however, capsule-based drug products can present significant formulation, manufacturing and supply challenges.
As small molecule pipelines continue to shift toward more complex, potent and sensitive active pharmaceutical ingredients (APIs) and as clinical trials similarly evolve toward adaptiveness and greater design, geographic and logistical complexity, the stepwise, linear model of development is no longer sufficiently robust. Instead, success increasingly depends on a thoughtful integration of formulation science, specialized filling capabilities and clinical supply planning from a program’s earliest stages.
Contract development and manufacturing organizations (CDMOs) that can not only excel in executing each of the critical capabilities but can efficiently interface among them are strongly positioned to help innovator companies avoid any downstream disruptions at the intersection of formulation constraints and clinical challenges.
Formulation Constraints Defining Manufacturability
Formulation decisions fundamentally define the performance of a drug product in patients, but they are also critical to determining what is practical to manufacture, scale, package and supply across the life of a clinical program. These constraints largely fall into three overlapping categories: physical, chemical and toxicological constraints.
Physical Properties and Manufacturing Yield
The powder behavior of the API is typically the primary physical challenge. Many development-stage APIs and blends exhibit poor flowability or a high degree of cohesion. These powder properties make capsule filling challenging, particularly at lower fill weights, which can have long-term impacts on manufacturing robustness and yield.
Bridging, poor die filling, segregation and inconsistent flow result in undesired outcomes, including rejected capsules, decreased yields and extended batch times, often requiring the establishment of conservative operating parameters that sacrifice throughput to maintain quality. A formulation issue that might present as manageable during development can ultimately translate into real yield loss and inefficiency once manufacturing advances into a GMP environment.
Chemical and Physicochemical Sensitivities
Moisture- or light-sensitive APIs and formulations typically require tightly controlled environments during manufacturing to preserve stability. To protect such products, processing is typically conducted under low-humidity conditions, but those conditions can make products more difficult to handle, increase static, and complicate both powder transfer and fill accuracy.
Manufacturers must often balance product protection against process operability, navigating adjustments to environmental controls, material-handling strategies, and equipment configuration to establish practical compromise solutions that protect both quality and manufacturing efficiency. Because CDMOs encounter a wide range of powder behaviors and formulation challenges across multiple programs, they often bring a broader base of experience in identifying and overcoming these issues than any single development team working on a single molecule.
Toxicity and Potency
Many OSD programs involve un-/under-characterized new chemical entities, potent or highly potent APIs, cytotoxic agents, hormones or controlled substances, each of which brings specific requirements for containment, facility design, scheduling, and the training of personnel. These requirements influence not only material handling but also where and when manufacturing can occur. Early, realistic planning that encompasses campaign development, equipment dedication, cleaning strategy and cross-contamination controls is essential to enabling the advancement of these programs.
Logistics Constraints Driven by Material Reality
Once a robust manufacturing process has been established for a formulation, the next limiting factor is often material availability. Both early-stage APIs and formulated drug products are often available in limited quantities, which leaves little margin for error.
A single formulation may need to support a host of activities, including process and analytical method development, preclinical studies, initial clinical supply, stability programs and shipping qualification — each drawing on the same, finite pool of material. That supply can be rapidly depleted by a range of inefficiencies (e.g., failed batches, duplicated studies, poorly aligned development work).
Budgeting these early development formulations is itself a significant challenge, and manufacturers and CDMOs that understand how to allocate deliberately, sequence activities intelligently, and avoid unnecessary loss of material can make the difference between program success and early-development failure.
Clinical Resupply as an Ongoing Risk
All of the above challenges are compounded by the reality of clinical trial resupply. In the context of fluctuating enrollment rates, expanding cohorts, evolving and adaptive protocols and shifting timelines, resupply is not a one-off contingency but a recurring operational risk that requires attention throughout the study.
Resupplying a clinical trial often requires more than just repeating a manufacturing run, as the evolution of a trial may require changes to packaging configurations, labeling, distribution routes and expectations around stability. Early integration among formulation, filling and supply is essential to avoiding resupply bottlenecks that can derail clinical studies. Performing formulation development and filling capsules at the same site can further reduce material loss, transfer risk and resupply delays.
Specialized Capsule Filling: Precision Under Constraint
These formulation and logistical constraints converge at capsule filling. This is particularly acute at lower dose targets, which require narrower tolerances and hence tighter control and a higher degree of execution difficulty.
The tighter acceptable tolerances associated with lower target doses mean greater sensitivity to the uniformity of blends, the behavior of the powder and the performance of the filling equipment. Minor variations that may have little consequence at high fill weights can present major challenges for lower fills. Cohesion and flow challenges that are tolerable earlier in development become critical at this stage, and acceptable fill performance may require specialized filling equipment, modified process parameters and tailored excipient systems, all of which can impact throughput, timelines and cost.
Environmental controls add an additional level of complexity during filling. For example, managing the competing demands of humidity control for moisture-sensitive formulations and the static-related fill challenges associated with low-humidity environments requires close coordination between experienced formulation and manufacturing teams.
Similarly, packaging configuration presents an additional technical variable that is often underestimated, because packaging is sometimes misunderstood as a neutral container rather than a critical part of the drug product system. The type and size of the capsule shell, as well as the primary packaging material, can all interact with fill accuracy, stability and other parameters. As such, packaging decisions can impact manufacturability, stability, shipping conditions and clinical viability.
Designing for Time: Stability, Packaging and Study Duration
Contemporary clinical trials can span months or even years across multiple regions and storage conditions, and the stability of a formulation must be ensured across the clinical life cycle. Robust packaging is key to protecting the drug product against light, moisture, oxidation and other factors through shipping, storage at clinical trials sites, and administration to patients. Materials that actively scavenge oxygen or moisture can be included to improve stability, but those inclusions bring their own operational and compatibility challenges.
These challenges are amplified by long or adaptive studies, as packaging that performs well for early-phase studies may be ineffective for later trials with greater duration or geographic scope. As even packaging changes mid-study can add to supply risk, it is essential to anticipate changes as early as possible.
Placebos and Blinding: A Formulation and Supply Challenge
The design of placebo drugs to enable effective blinding is itself a challenge impacting both formulation and supply, as placebos must match the appearance, weight, and other characteristics of the active drug product as closely as possible. Again, these challenges become particularly acute for low-dose or sensitive formulations, typically requiring separate but interlinked formulation, filling, packaging and stability considerations for the placebo and the active drug product. Additionally, careful planning is needed to synchronize the supply of both active and placebo drugs throughout a trial, including resupply and following protocol evolution.
Using QbD to Align Science with Clinical Realities
Quality by design (QbD) provides a pragmatic framework under which to align these interacting constraints. Interactions with clinical teams help to define a quality target product profile (QTPP), distinguishing critical quality attributes (CQAs) that must be achieved from attributes that are merely desirable. Next, risk management identifies the factors that must be studied and tightly controlled going forward, and design-of-experiments (DoE) studies can interrogate the relationships among critical material attributes (CMAs), critical process parameters (CPPs), and CQAs to optimize the robustness of manufacturing and the reliability of supply and to align with regulatory expectations.
Project Management Under Real Constraints
Regardless of the strength of the technical foundations underlying a program, success is determined by execution. At an effective CDMO, project management provides the structure through which the CDMO and client can collaborate to determine what can realistically be achieved within a given time frame, what technical and commercial risks must be avoided and what are being accepted (e.g., accepting limited stability data in order to meet a clinical milestone), and what activities can and should proceed in parallel. Some level of tradeoffs is generally unavoidable but making them explicit allows teams to work deliberately in anticipation of negative outcomes rather than reactively.
Integration as a Competitive Advantage
The most significant challenges facing drug development programs advancing into the clinic rarely emerge from a single activity, but rather at key intersections: between formulation and manufacturability, filling and packaging, and production and clinical supply. Manufacturers and CDMOs that can integrate these disciplines and capabilities can not only effectively solve these challenges but also help to anticipate and avoid them.
For small and medium-sized biopharma companies navigating the path from capsule filling challenges to clinical supply complexity — especially for the first time — a focused and integrated CDMO partner can understand and minimize risk, improve predictability and enable development programs to advance with momentum and confidence.